Fetzima(Levomilnacipran Hcl)
ABBV
Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by AbbVie Inc.
$27.0M
Medicare cost, 2024
$27.0M
Medicare cost, 2024
Medicare drug plans spent $27.0 million on Fetzima (levomilnacipran hcl) in 2024, for 39,239 prescriptions and refills filled by 5,787 patients. Ohio accounts for the most spending ($1.9 million, 7% of the total). It is made by AbbVie Inc. (ABBV).
Medicare cost, 2024
$27.0M
-7.7% from 2023
Prescriptions
39K
$689.21 per claim
Patients
5,787
5,863 prescribers
Total spending, 2024
$27.1M
$4,676.06 per patient
Questions and answers
How much does Medicare spend on Fetzima?
Medicare prescription drug plans paid $27.0M for Fetzima in 2024, for 39,239 prescriptions and refills to 5,787 patients (down 7.7% from 2023). The average cost per claim was $689.21.
Which state spends the most on Fetzima?
Ohio had the highest Medicare cost for Fetzima in 2024: $1.9M for 3,043 claims, followed by California ($1.9M).
Who prescribes Fetzima the most?
Alexander Pinkusovich, psychiatry in Brooklyn, NY, had the highest Medicare cost for Fetzima in 2024: 135 claims costing $65K.
Who makes Fetzima?
Fetzima is made by AbbVie Inc. (ABBV), listed in the Medicare spending data as Forest/Allergan.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Fetzima was $27.1M in 2024, after a high of $30.6M in 2020.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Fetzima, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Alexander Pinkusovich Brooklyn, NY | Psychiatry | 135 | 20 | $65K |
| Timothy R Rasmussen Waite Park, MN | Psychiatry | 104 | Under 11 | $52K |
| Julia E Lansing Columbus, OH | Certified Clinical Nurse Specialist | 75 | Under 11 | $45K |
| John C Ciaccio Moline, IL | Psychiatry | 77 | Under 11 | $44K |
| Stephen L Dilts Jr. York, PA | Psychiatry | 15 | Under 11 | $41K |
| Joseph Luzius Albuquerque, NM | Psychiatry | 69 | Under 11 | $40K |
| Matthew A Bayer Menasha, WI | Psychiatry | 58 | Under 11 | $36K |
| Pamela Schwartz Warsaw, IN | Nurse Practitioner | 44 | Under 11 | $36K |
| Roy B del-Rosario Lancaster, CA | Psychiatry | 60 | Under 11 | $36K |
| Francis S Penland Hickory, NC | Nurse Practitioner | 25 | Under 11 | $35K |
| Wendy L Corriveau Dearborn, MI | Nurse Practitioner | 12 | Under 11 | $35K |
| Jennifer C Heath Fort Worth, TX | Psychiatry & Neurology | 60 | Under 11 | $35K |
| Ryan M Bednar Medina, OH | Nurse Practitioner | 39 | Under 11 | $34K |
| Angela C Hammond Memphis, TN | Nurse Practitioner | 34 | Under 11 | $33K |
| Rebecca A Moore Madelia, MN | Nurse Practitioner | 53 | Under 11 | $32K |
| Shannon Harding Salt Lake City, UT | Nurse Practitioner | 30 | Under 11 | $32K |
| William Bara-Jimenez Kensington, MD | Neurology | 46 | Under 11 | $30K |
| Tania C Martinez-Jimenez Bethlehem, PA | Psychiatry | 21 | Under 11 | $30K |
| Joseph C Shanklin Clearwater, FL | Psychiatry | 19 | Under 11 | $30K |
| Jonathan C Uecker New Brighton, MN | Psychiatry | 48 | Under 11 | $29K |
| Lee S Spain Meadville, PA | Psychiatry | 52 | Under 11 | $29K |
| Nicholas Tobin Longmeadow, MA | Nurse Practitioner | 43 | Under 11 | $29K |
| Peter E Neifert Staples, MN | Psychiatry | 44 | Under 11 | $28K |
| Alfred E Buxton Lafayette, LA | Psychologist, Clinical | 47 | Under 11 | $28K |
| Sonia Motin Kalamazoo, MI | Psychiatry | 37 | 11 | $28K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2022 | 6,707 | 46,663 | 6,681 | $29.8M |
| 2023 | 6,366 | 42,710 | 6,276 | $29.3M |
| 2024 | 5,863 | 39,239 | 5,787 | $27.0M |
Makers, 2024
Spending by manufacturer as listed in the spending data
| Manufacturer | Claims | Spending |
|---|---|---|
| Forest/Allergan | 39,287 | $27.1M |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 10
- RxNorm concept IDs
- 1433217, 1433223, 1433227, 1433229, 1433233
- Application numbers
- NDA204168
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 1,929 side-effect reports named levomilnacipran hydrochloride, the active ingredient of Fetzima (reports from 2013 on). 1,027 of them (53.2%) were serious, 176 named a death and 320 named a hospital stay. The reactions named most often were off label use, drug ineffective and pain. 532 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
1,929
158 in 2025 (+116.4% from 2024)
Serious
53.2%
1,027 reports
Deaths named
176
9.1% of reports
Hospital stays
320
16.6% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Fetzima?
1,929 reports from 2013 through September 2026 named levomilnacipran hydrochloride, the active ingredient of Fetzima. 1,027 of them (53.2%) were serious, 176 named a death and 320 named a hospital stay.
What are the most reported side effects of Fetzima?
350 reports named off label use, the reaction named most often, followed by drug ineffective (266) and pain (225). In the last 5 years the reaction named most often was off label use (217 reports). A report can name several reactions.
How many side-effect reports named Fetzima in 2025?
158 reports were received in 2025 (+116.4% from 2024). 2026 so far: 68 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Fetzima caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Fetzima caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Makers on the stock market:
ABBV·ABBV drug pipeline - Drug approvals (1 approval on file for levomilnacipran hydrochloride) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (levomilnacipran hydrochloride) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.